Acute myeloid leukemia with recurrent genetic anomaly

Last reviewed March 21, 2026

🖨 Print for my doctor Advocacy Hub →

ORPHA:98277OMIM:601626

Who is this for?

Show terms as

1Active trials 8Specialists 8Treatment centers

Where are you in your journey?

ℹ

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.

Report missing data

Overview

Also known as:

Acute myeloid leukemia AML AML with recurrent genetic anomaly

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

3 events

Dec 2025HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Hangzhou Polymed Biopharmaceuticals, Inc. — PHASE1

TrialNOT YET RECRUITING

Aug 2025Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

National Cancer Institute (NCI) — PHASE1

TrialRECRUITING

Mar 2005

Temodar: FDA approved

Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Acute myeloid leukemia with recurrent genetic anomaly.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →

Phase 11 trial

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1

Actively Recruiting

PI: Evan C Chen (Dana-Farber - Harvard Cancer Center LAO) · Sites: New Haven, Connecticut; Atlanta, Georgia +16 more · Age: 18–99 yrs

Specialists

8 foundView all specialists →

EC

Evan C Chen

Specialist

PI on 1 active trial

Active trials Directions Travel grants

GC

George Chen

Specialist

Acute myeloid leukaemia with myelodysplasia-related features Acute radiation syndrome Aggressive NK-cell leukemia+28 more

PI on 2 active trials

Active trials Directions Travel grants

PM

Philip L. McCarthy, MD

Specialist

Acquired idiopathic sideroblastic anemia Acute mast cell leukemia AL amyloidosis+10 more

PI on 7 active trials

Active trials Directions Travel grants

TM

Thomas J. Walsh, MD

Specialist

Acute lymphoblastic leukemia Agranulocytosis Aspergillosis+6 more

PI on 6 active trials

Active trials Directions Travel grants

GM

Gregory Yanik, MD

ANN ARBOR, MI

Specialist

Complications after hematopoietic stem cell transplantation Congenital Epstein-Barr virus infection Myeloid sarcoma+1 more

PI on 2 active trials1 Acute myeloid leukemia with recurrent genetic anomaly publication

Active trials Directions Travel grants

AM

Ann E. Woolfrey, MD

SEATTLE, WA

Specialist

Acute erythroid leukemia Acute mast cell leukemia Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent+1 more

PI on 5 active trials

Active trials Directions Travel grants

KM

Kenneth G. Lucas, MD

Specialist

Acute mast cell leukemia Acute myeloid leukemia with 11q23 abnormalities Adult T-cell leukemia/lymphoma+40 more

PI on 7 active trials

Active trials Directions Travel grants

MM

Mary C. Territo, MD

LOS ANGELES, CA

Specialist

Acute biphenotypic leukemia Complex vascular malformation with associated anomalies Genetic complex vascular malformation with associated anomalies+2 more

PI on 3 active trials

Active trials Directions Travel grants

Treatment Centers

8 centers

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Acute myeloid leukemia with recurrent genetic anomaly.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Acute myeloid leukemia with recurrent genetic anomalyForum →

No community posts yet. Be the first to share your experience with Acute myeloid leukemia with recurrent genetic anomaly.

Start the conversation →

Latest news about Acute myeloid leukemia with recurrent genetic anomaly

Disease timeline:

New recruiting trial: Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

A new clinical trial is recruiting patients for Acute myeloid leukemia with recurrent genetic anomaly

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Acute myeloid leukemia with recurrent genetic anomaly

Are there clinical trials for Acute myeloid leukemia with recurrent genetic anomaly?

Yes — 1 recruiting clinical trial is currently listed for Acute myeloid leukemia with recurrent genetic anomaly on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Acute myeloid leukemia with recurrent genetic anomaly?

8 specialists and care centers treating Acute myeloid leukemia with recurrent genetic anomaly are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.